Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir
E Martinez(Hospital Clínic de Barcelona), Eugènia Negredo(Universitat de Vic - Universitat Central de Catalunya), José Ignacio Bernardino(Hospital Universitario La Paz), Adrián Curran(Lexington City Schools), JA Cartón(Universidad de Oviedo), Félix Gutiérrez(Universitat de Miguel Hernández d'Elx), Javier Murillas, Ana Gonzalez‐Cordón, Ignacio de los Santos, Judit Pich(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Joaquín Portilla(Hospital General Universitario de Alicante Doctor Balmis), Ignacio Pérez(Apple (Israel)), Peré Domingo(Hospital de Sant Pau), Daniel Podzamczer(Bellvitge University Hospital), Joaquim Peraire(Instituto de Salud Carlos III), Elena Ferrer(Hospital Universitari Germans Trias i Pujol), JM Gatell(Hospital Clínic de Barcelona)
Cited by 32
Related Papers
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care
|Clinical Infectious Diseases|2020|171
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143